Blood marker test in newly diagnosed PBC patients
Treatments studied
Part of Digestive system clinical trials.
This study looks at how a specific blood marker (sCD163) changes in people newly diagnosed with primary biliary cholangitis (PBC). It’s mainly meant to see whether this marker could help predict treatment response, especially before starting UDCA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were newly diagnosed with PBC
- You have not taken UDCA (a common PBC medicine) before joining
- You are 18 years or older
- You are expected to live at least 6 months
- You are not planning a liver transplant within the next 6 months
- You do not have liver cancer or cirrhosis caused by another disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects and stores samples from people with PSC (primary sclerosing cholangitis), PBC (primary biliary cholangitis), and some related liver conditions. Researchers use these samples to better understand these diseases and support future research.
This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
This trial studies whether fenofibrate (a cholesterol medicine) can improve outcomes in people with primary biliary cholangitis (PBC) who already take ursodeoxycholic acid (UDCA) but still have abnormal liver blood tests. It specifically looks at people with “compensated” (stable) cirrhosis—meaning the liver disease is present but not causing severe complications right now.
This study looks at the characteristics and progression of primary biliary cholangitis (PBC), a chronic liver disease. It aims to find factors that may lead to worsening of the disease, which could help improve future care.
This study looks at how well two medicines, ursodiol and seladelpar, work together for people with primary biliary cholangitis (PBC), a liver disease. It may help doctors understand the best way to treat PBC and improve liver health.
Hear when a new Primary Biliary Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.